PT Medela Potentia Records 16% Net Profit Growth in 2025

Jakarta (ANTARA) - PT Medela Potentia Tbk (MDLA) recorded double-digit net profit growth of 16% year-on-year, reaching Rp398.1 billion, supported by revenue growth of Rp14.89 trillion in 2025. According to Medela Potentia’s President Director Krestijanto Pandji, the strengthening of distribution networks, principal expansions, and growth in digital business and medical devices bolstered the company’s performance amid healthcare industry dynamics. This achievement, he continued in his statement in Jakarta on Tuesday, reflects the stability of the company’s fundamental business, supported by strengthened distribution systems and operational optimisation. “Double-digit net profit growth is one of the positive indicators of the company’s performance throughout 2025. Moving forward, the company will remain focused on maintaining growth stability through strengthening logistics infrastructure and optimising its business portfolio,” he stated. Throughout 2025, the company strengthened its business portfolio by adding eight new principals, consisting of two prescription drug principals, two consumer health principals, and four medical device principals. This diversification is expected to enrich the distribution solutions offered while enhancing the company’s competitiveness in the healthcare industry. On the infrastructure side, according to Krestijanto, the company also continued to strengthen its distribution capabilities as part of a strategy to increase capacity and operational efficiency. In May 2025, the company acquired National Distribution Center (NDC) 1, covering 10,000 square metres with a capacity of 13,525 pallets in the Jababeka II Industrial Estate, Cikarang, West Java, which has been an integral part of the company’s distribution infrastructure for more than 10 years and was previously utilised through a lease scheme from an affiliated company. Additionally, the company acquired 2.7 hectares of land in the Jababeka I Industrial Estate, planned for the development of NDC 2 for PT Anugrah Argon Medica. “This expansion will further strengthen warehouse capabilities while improving the speed and quality of service to customers,” he said. To expand distribution reach in the Sumatra region, the construction of a warehouse and branch office for PT Anugrah Argon Medica in Medan is targeted for completion by the end of 2026. From the medical devices business line, the company’s subsidiary, PT Deca Metric Medica (DMM), began expanding into international markets by exporting medical device products to Cambodia and Timor Leste in August 2025. Meanwhile, the company’s marketing entity in the medical devices sector, PT Djembatan Dua, also continued to strengthen its own brand portfolio by launching three SKUs of products, supporting total sales growth of 50%. In the digital business line, the GoApotik platform recorded revenue growth of 32% with a 24% increase in customer transactions compared to the previous year. On that occasion, Krestijanto also stated that the company collaborated with regulators on education regarding Good Drug Distribution Practices (CDOB) as part of the company’s contribution to improving healthcare service quality in Indonesia. On the environmental aspect, the company implemented the use of electric motor-based operational vehicles to support energy efficiency and carbon emission reduction. By the end of 2025, the use of electric motorcycles had been implemented in 15 branches across 13 cities, with a total of 106 units.